RALEIGH, N.C., Oct. 24, 2016 -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization, today announced it has been awarded the 2016 Frost & Sullivan Asia Pacific Contract Research Outsourcing Services Customer Value Leadership Award. The Company was recognized for successfully expanding its customer base in the Asia/Pacific region and driving significant repeat business while demonstrating a consistent focus on helping to speed/accelerate the delivery of ground-breaking products to market. Other successes that contributed to INC’s selection included the ability to nurture the right environment and attitudes for innovation, tailoring its strategy to local conditions and making concerted efforts to improve customer satisfaction. INC accepted the award at the Frost & Sullivan Asia Pacific Best Practices Awards gala Oct. 13 in Singapore.
“INC Research’s ability to anticipate and meet market demand through quality and innovative clinical research services has enabled it to grow sustainably in this competitive industry,” said Sanjeev Kumar, Industry Manager, Healthcare Practice, Frost & Sullivan. “Building on its strengths, INC Research has emerged as the leader in providing unparalleled customer value in the CRO industry. The Company has triumphed in this space as a result of its ability to identify unmet needs and to offer innovative solutions.”
Frost & Sullivan, a leading growth consulting firm, also recognized INC Research’s expertise in the management of complex clinical trials in areas such as oncology and central nervous systems (CNS), which can be attributed to its therapeutically-specialized teams working across Phase I to IV clinical development. This eliminates barriers such as time, language and distance to achieve high productivity and rapid turnaround times to better serve customers.
“In a very short period of time, we have differentiated INC through a strong reputation grounded by our therapeutic focus, deep knowledge of local regulations and medical practices and full-service capabilities across the region,” said Alan Ong, Executive Vice President, Asia/Pacific and Global Head, Medical Devices, INC Research. “This award speaks to the hard work and dedication of our employees in continuing to deliver superior customer value and operational excellence to our customers. We are honored to be recognized by Frost & Sullivan, and will continue to focus on establishing INC Research as CRO of Choice in the region.”
INC Research’s presence in the Asia/Pacific region includes locations in Japan, China, India, Australia, Singapore, Philippines, South Korea, Taiwan, Hong Kong, Malaysia, Thailand, Indonesia and New Zealand. The Company has a long history of providing Phase I to IV clinical development services in these countries, conducting more than 1,800 studies across a broad range of therapeutic areas.
Held annually in Singapore, the Frost & Sullivan Asia Pacific Best Practices Awards program recognizes best-in-class companies in Asia/Pacific for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research in order to identify best practices in the industry.
About INC Research
INC Research (Nasdaq:INCR) is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. The Company was named “Best Contract Research Organization” in December 2015 by an independent panel for Scrip Intelligence, and ranked “Top CRO to Work With” among large global CROs in the 2015 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 110 countries. For more information, please visit www.incresearch.com and connect with us on LinkedIn and Twitter @inc_research.
CONTACT: Investor Relations Contact: Ronnie Speight Vice President, Investor Relations Phone: +1 (919) 745-2745 Email: [email protected] Press/Media Contacts: Lori Dorer Senior Director, Corporate Communications Phone: +1 (513) 763-1380 Email: [email protected]


Bill Ackman Eyes New Fund to Bet Against Market Complacency
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 



